[HTML][HTML] Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis
T Pitre, J Su, S Cui, R Scanlan… - European …, 2022 - Eur Respiratory Soc
Background: There is no consensus on the most effective treatments of pulmonary arterial
hypertension (PAH). Our objective was to compare effects of medications for PAH. Methods …
hypertension (PAH). Our objective was to compare effects of medications for PAH. Methods …
[HTML][HTML] Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era
JGE Zelt, J Sugarman, J Weatherald… - European …, 2022 - Eur Respiratory Soc
Background The evolution in pulmonary arterial hypertension (PAH) management has been
summarised in three iterations of the European Society of Cardiology/European Respiratory …
summarised in three iterations of the European Society of Cardiology/European Respiratory …
[HTML][HTML] Treatment of pulmonary hypertension associated with COPD: a systematic review
R Arif, A Pandey, Y Zhao, K Arsenault-Mehta… - ERJ Open …, 2022 - Eur Respiratory Soc
Chronic obstructive pulmonary disease-associated pulmonary hypertension (COPD-PH) is
an increasingly recognised condition which contributes to worsening dyspnoea and poor …
an increasingly recognised condition which contributes to worsening dyspnoea and poor …
Canadian Cardiovascular Society: clinical practice update on cardiovascular management of the pregnant patient
J Windram, J Grewal, N Bottega, M Sermer… - Canadian Journal of …, 2021 - Elsevier
The number of women of childbearing age with cardiovascular disease (CVD) is growing
because of increased survival of children with congenital heart disease. More women are …
because of increased survival of children with congenital heart disease. More women are …
[HTML][HTML] The Early Detection of Pulmonary Hypertension
L Ley, F Grimminger, M Richter, K Tello… - Deutsches Ärzteblatt …, 2023 - ncbi.nlm.nih.gov
Background Up to 1% of the world population and 10% of all persons over age 65 suffer
from pulmonary hypertension (PH). The latency from the first symptom to the diagnosis is …
from pulmonary hypertension (PH). The latency from the first symptom to the diagnosis is …
Clinical application of risk assessment in PAH: expert center APRN recommendations
M Wilson, J Keeley, M Kingman, S McDevitt… - Pulmonary …, 2022 - Wiley Online Library
Performing longitudinal and consistent risk assessments for patients with pulmonary arterial
hypertension (PAH) is important to help guide treatment decisions to achieve early on and …
hypertension (PAH) is important to help guide treatment decisions to achieve early on and …
Treatments for pulmonary arterial hypertension: navigating through a network of choices
T Pitre, J Weatherald, M Humbert - European Heart Journal, 2024 - academic.oup.com
The treatment landscape for PAH has evolved dramatically over the past 30 years. 3
Medications targeting the endothelin, nitric oxide, and prostacyclin pathways have been …
Medications targeting the endothelin, nitric oxide, and prostacyclin pathways have been …
Role of oxidative stress versus lipids in monocrotaline‐induced pulmonary hypertension and right heart failure
F Farahmand, A Malik, A Sharma… - Physiological …, 2021 - Wiley Online Library
Pulmonary hypertension (PH) is a global health issue with a prevalence of 10% in ages> 65
years. Right heart failure (RHF) is the main cause of death in PH. We have previously shown …
years. Right heart failure (RHF) is the main cause of death in PH. We have previously shown …
Prognostic Potential of Pulmonary Hypertension in Patients with Hematologic Malignancy
M Li, M Tang, C Zhao, P Dang, X Wang, H Liu… - Advances in …, 2023 - Springer
Introduction Cardiovascular diseases present a great burden for survivors of hematologic
malignancy (HM). However, the effect of pulmonary hypertension (PH) on the clinical …
malignancy (HM). However, the effect of pulmonary hypertension (PH) on the clinical …
The incidence and prevalence of pulmonary hypertension in the COPD population: a systematic review and meta-analysis
L Zhang, Y Liu, S Zhao, Z Wang, M Zhang… - … Journal of Chronic …, 2022 - Taylor & Francis
Purpose Chronic obstructive pulmonary disease (COPD)-related pulmonary hypertension
(PH) is one of the most common comorbidities of COPD, and often leads to a worse …
(PH) is one of the most common comorbidities of COPD, and often leads to a worse …